UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 195

Sortiert nach

136O Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S115-S115

2016

Volltextzugriff (PDF)

1551 Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: A qualitative interview sub-study

European journal of cancer (1990), 2015-09, Vol.51, p.S221-S221

2015

Volltextzugriff (PDF)

3030 Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S606-S606

2015

Volltextzugriff (PDF)

Activation of E-prostanoid4 and e-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages

The European respiratory journal, 2007-05, Vol.29 (5), p.986-994

2007

Volltextzugriff (PDF)

Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1β-driven model of joint pathology

Osteoarthritis and cartilage, 2009-06, Vol.17 (6), p.790-797

2009

Volltextzugriff (PDF)

Screening and Intervention to Prevent Falls and Fractures in Older People

The New England journal of medicine, 2020-11, Vol.383 (19), p.1848-1859

2020

Volltextzugriff (PDF)

Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-{alpha} release from human alveolar macrophages

The European respiratory journal, 2007-05, Vol.29 (5), p.986-994

2007

Volltextzugriff (PDF)

354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)

Annals of oncology, 2023-10, Vol.34, p.S323-S324

2023

Volltextzugriff (PDF)

P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S258-S258

2021

Volltextzugriff (PDF)

83 AN ACUTE IL-1 MEDIATED MODEL OF JOINT DESTRUCTION

Osteoarthritis and cartilage, 2007, Vol.15, p.C56-C57

2007

Volltextzugriff (PDF)

Human peripheral blood mononuclear cells express GABA A receptor subunits

Molecular immunology, 2006-03, Vol.43 (9), p.1432-1442

2006

Volltextzugriff (PDF)

139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S81-S82

2018

Volltextzugriff (PDF)

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S507-S508

2018

Volltextzugriff (PDF)

Heterogeneity of resting-state EEG features in juvenile myoclonic epilepsy and controls

Brain communications, 2022, Vol.4 (4), p.fcac180-fcac180

2022

Volltextzugriff (PDF)

Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses

European journal of immunology, 2004-02, Vol.34 (2), p.565-575

2004

Volltextzugriff (PDF)

Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC): 139PD

Journal of thoracic oncology, 2018-04, Vol.13 (4 Suppl), p.S81-S82

2018

Volltextzugriff (PDF)

Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1beta-driven model of joint pathology

Osteoarthritis and cartilage, 2009-06, Vol.17 (6), p.790-797

2009

Volltextzugriff (PDF)

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial: 136O

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S115-S115

2016

Volltextzugriff (PDF)

Rapid simultaneous cloning of drug targets from multiple mammalian species

Alternatives to laboratory animals, 2006-06, Vol.34 (3), p.295-303

2006

Volltextzugriff (PDF)

New Zealand's foreign policy towards Asia [address]

New Zealand Foreign Affairs Review, 1974-07, Vol.24, p.11-17

Walding, J A

1974

Volltextzugriff (PDF)

Characterising Australians who have high levels of anger towards islam and muslims

Journal of sociology (Melbourne, Vic.), 2024-03, Vol.60 (1), p.99–120-99–120

2024

Volltextzugriff (PDF)

Sport And Recreation

Journal of physical education, recreation & dance, 1973-07, Vol.6, p.14-14

Walding, JA

1973

Volltextzugriff (PDF)

Cardiac Safety of Osimertinib: A Review of Data

Journal of clinical oncology, 2021-02, Vol.39 (4), p.328-337

2021

Volltextzugriff (PDF)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Volltextzugriff (PDF)

Australians' divergent opinions about Islam and Muslims

Journal of sociology (Melbourne, Vic.), 2022-03, Vol.58 (1), p.45-58

2022

Volltextzugriff (PDF)

1 – 25 von 195

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(160)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(195)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(43)
Humans
(37)
Physical Sciences
(31)
Physics
(28)
Physics, Particles & Fields
(19)
Dark Matter
(14)
Male
(14)
Biological And Medical Sciences
(13)
Female
(13)
Animals
(12)
Astronomy & Astrophysics
(11)
Medical Sciences
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Neoplasms - Drug Therapy
(10)
Oncology
(10)
Pediatrics
(10)
Argon
(9)
Physics Of Elementary Particles And Fields
(9)
Technology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

136O Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

1551 Patient experience of symptoms and side effects when treated with AZD9291 for advanced non-small-cell lung cancer: A qualitative interview sub-study

3030 Patient-reported symptom response and impact of treatment with AZD9291 for advanced non-small-cell lung cancer

Activation of E-prostanoid4 and e-prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages

Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1β-driven model of joint pathology

Screening and Intervention to Prevent Falls and Fractures in Older People

Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-{alpha} release from human alveolar macrophages

354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)

P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA

83 AN ACUTE IL-1 MEDIATED MODEL OF JOINT DESTRUCTION

Human peripheral blood mononuclear cells express GABA A receptor subunits

139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Heterogeneity of resting-state EEG features in juvenile myoclonic epilepsy and controls

Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses

Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC): 139PD

Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1beta-driven model of joint pathology

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial: 136O

Rapid simultaneous cloning of drug targets from multiple mammalian species

New Zealand's foreign policy towards Asia [address]

Characterising Australians who have high levels of anger towards islam and muslims

Sport And Recreation

Cardiac Safety of Osimertinib: A Review of Data

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Australians' divergent opinions about Islam and Muslims

Suchergebnisse filtern